STAFF BOARD
Article
CHAIRMAN
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 21 - Issue 2, March-April 2019
SHORT REPORTS
A CASE REPORT OF DALBAVANCIN OFF-LABEL USE IN A 4 YEARS OLD PEDIATRIC PATIENT
GÓMEZ DE RUEDA FÉLIX, TENA SEMPERE MARÍA EUGENIA, MARTÍNEZ PADILLA MARÍA DEL CARMEN, SANTIAGO GUTIÉRREZ CARMEN, DE LA CRUZ MORENO JESÚS


The choice of the appropriate antibiotic could represent a difficulty due to the responsible bacteria, the individual variability and the anatomical location of the infections. The aim of this case report is to share a sentinel experience of a gram-positive infection in a pediatric patient, which was refractory to conventional treatment but successfully responded to dalbavancin. We describe a community- acquired pneumonia of long evolution, with no response to the usual antibiotic treatment. Despite the antibiotics used, the levels of acute phase reagents, leukocytes, liver enzymes, glucidic profile and renal markers increased until dalbavancina was started. After a load dose weight of 15 mg/kg and three maintenance doses of 7.5 mg/kg, the patient responded clinically. Certain antibiotics can be used if necessary in the pediatric population like an Off-Label use. Hospital pharmacists play an important role in the selection and management of the appropriate antibiotic, especially in resistant cases.

DALBAVANCIN – PEDIATRIC – RESPIRATORY INFECTION



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25